Cortico-Striatal-Thalamic Loop Circuits of the Orbitofrontal Cortex: Promising Therapeutic Targets in Psychiatric Illness
O artigo “Cortico-Striatal-Thalamic Loop Circuits of the Orbitofrontal Cortex: Promising [...]
Depoimentos de pacientes que foram tratados com rTMS
CVL (Depressão severa com risco alto de suicídio considerando avaliação [...]
Transcranial Magnetic Stimulation and Major Depression
Transcranial Magnetic Stimulation and Major Depression Estimulação Magnética Transcraniana e [...]
The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder
Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4-6 weeks (20-30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated in 2013.
Diretrizes baseadas em evidências sobre o uso terapêutico da estimulação magnética transcraniana repetitiva (EMTr)
A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion.